Content
3 Buy Rated Stocks To Consider As Earnings Approach
Article By:
Zacks Investment Research
Read
Saturday, April 13, 2024 2:20 AM EDT
With the Q1 earnings season underway, there will be a microscope on companies that can continue to show improvements in their outlook amid an uptick in inflation.
Low Beta Tech Stocks To Consider For A Rebound Amid Heightened Market Volatility
Article By:
Zacks Investment Research
Read
Friday, April 12, 2024 10:20 PM EDT
With market volatility heating up investors will surely be looking for opportunities in the tech sector. After all, the Nasdaq is still up +7% year to date and has soared +32% over the last year despite dipping -1% so far this month.
Abbott Laboratories Dividend Stock Analysis
Article By:
Dividends4Life
Read
Friday, April 12, 2024 7:00 AM EDT
Abbott Laboratories discovers, develops, manufactures, and sells healthcare products. Its products include branded generic pharmaceuticals manufactured internationally, marketed, and sold outside the United States.
In this article: ABT
Current Analysis: Sonic Healthcare Limited
Article By:
Fredrik Arnold
Read
Thursday, April 11, 2024 9:45 PM EDT
Sonic Healthcare is a global pathology provider. Over the past year, Sonic’s share price fell 20.2% from $23.78 to $18.97 as of Thursday’s market close.
In this article: SKHCF
Current Analysis: Pfizer (PFE)
Article By:
Fredrik Arnold
Read
Wednesday, April 10, 2024 8:15 PM EDT
Pfizer (PFE) is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Over the past year, Pfizer’s share price fell 36.6% from $41.50 to $26.31 as of Wednesday’s market close.
Tilray's Q3 Financials Disappoint: Stock Declines 31%
Article By:
Lorimer Wilson
Read
Wednesday, April 10, 2024 6:46 PM EDT
Tilray's stock price is down 30.9% from its high last week as a result of the release of its disappointing Q3 financial results yesterday.
In this article: TLRY
Current Analysis: Takeda Pharmaceutical
Article By:
Fredrik Arnold
Read
Tuesday, April 9, 2024 8:55 PM EDT
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. Over the past year, Takeda’s share price fell 20.5% from $34.04 to $27.05 as of Tuesday’s market close.
In this article: TKPHF
Current Analysis: Elekta AB
Article By:
Fredrik Arnold
Read
Monday, April 8, 2024 10:00 PM EDT
Sweden-based Elekta AB is a medical technology company, providing clinical solutions for treating cancer and brain disorders worldwide.
In this article: EKTAF
Healthcare ETFs For The Weight-Loss Drug Boom And Beyond
Podcast By:
Neena Mishra
Listen
Monday, April 8, 2024 6:30 PM EDT
Two dominant investing themes over the past year have been AI and weight-loss drugs.
Latest Analysis: BioGaia (BIOGY)
Article By:
Fredrik Arnold
Read
Sunday, April 7, 2024 8:48 PM EDT
We're revisiting BIOGY, which since our last coverage in February has seen its share price rise 18%.
In this article: BIOGY
Grow Your Bottom Line As Demand Increases For These Robots
Article By:
Brad Thomas
Read
Saturday, April 6, 2024 12:20 PM EDT
Today, I’ll explain why there’s a growing need for more robots to do surgery. I’ll also show you how to collect a reliable yield while investing in a company that’s developing new surgical robots.
Is Amgen The Rare Biotech With A Safe Dividend?
Article By:
Marc Lichtenfeld
Read
Wednesday, April 3, 2024 8:10 PM EDT
Amgen pays a $2.25 per share quarterly dividend, which comes out to a 3.3% yield. Biotech can be notoriously volatile, though, so can investors count on receiving the same dividend quarter after quarter?
In this article: AMGN